[
  {
    "ts": null,
    "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
    "summary": "Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.",
    "url": "https://finnhub.io/api/news?id=3249a8719f18225cae6a6ba6eb48579d644ad4f0e96c83d6272ddebd4ea8b987",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733585940,
      "headline": "Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?",
      "id": 131846402,
      "image": "https://g.foolcdn.com/editorial/images/800011/dollar-bills-and-coins-on-a-calendar.jpg",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Looking for reliable income in the stock market? You might want to consider the top Dogs of the Dow in December. Here's what you need to know about this trio of blue-chip stocks.",
      "url": "https://finnhub.io/api/news?id=3249a8719f18225cae6a6ba6eb48579d644ad4f0e96c83d6272ddebd4ea8b987"
    }
  },
  {
    "ts": null,
    "headline": "BLINCYTO速 (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)",
    "summary": "Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO速 (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of",
    "url": "https://finnhub.io/api/news?id=da0f91c5a9cb7a9fb96d8bf0d5d8029e237004514644c4e6002deb0502a64711",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1733583600,
      "headline": "BLINCYTO速 (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)",
      "id": 131849928,
      "image": "https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO速 (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of",
      "url": "https://finnhub.io/api/news?id=da0f91c5a9cb7a9fb96d8bf0d5d8029e237004514644c4e6002deb0502a64711"
    }
  }
]